Hot melt extrusion and its pharmaceutical applications

Asian Journal of Pharmaceutical Sciences

Volumn 7, Issue 2, 2012, Pages 123-133

  Madan, Sarika ^a   Madan, Sumit ^b  

^a UNIVERSITY OF DELHI   (India)

^b Ranbaxy Laboratories Limited   (India)

Author keywords

Amorphous materials; Bioavailability enhancement; Extruder; Plasticizers; Polymers; Solubility enhancement; Sustained release systems; Taste masking

Indexed keywords

CITRIC ACID TRIETHYL ESTER; ETHYL CELLULOSE; GLYCEROL STEARATE; HYDROXYPROPYLCELLULOSE; MACROGOL; PHTHALIC ACID DIETHYL ESTER; PLASTICIZER; POLYMER; POLYMETHACRYLIC ACID; PROPYLENE GLYCOL; SEBACIC ACID DIBUTYL ESTER; TRIACETIN;

BIOAVAILABILITY; BIOLOGICAL MONITORING; CHEMICAL MODIFICATION; CHEMICAL REACTION; CONTROLLED DRUG RELEASE; COOLING; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SOLUBILITY; GOOD MANUFACTURING PRACTICE; HEATING; HIGH TEMPERATURE; HOT MELT EXTRUSION; MOISTURE; REVIEW; SCIENTIFIC LITERATURE; SHEAR STRESS; THERMOSTABILITY;

EID: 84871406123     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Andrews GPJ, David S, Osama AM, et al. Hot melt extrusion: an emerging drug delivery technology. Pharm Tech Eur. 2009, 21: 24-27.
2. McGinity JW, Koleng JJ, Repka MA, et al. hot-melt extrusion technology. In: Swarbrick J, Boylan JC, editors. Encyclopedia Pharm Technol. Ed. 2nd supplement. New York: Marcel Dekker, 2000. 19: 203-226.
3. Williams M, Tian Y, Jones DS, et al. Hot melt extrusion technology: optimizing drug delivery. European Industrial Pharmacy. 2010, 7: 7-10.
4. Young CR, Crowley M, Dietzsch C, et al. Physicochemical properties of film-coated melt-extruded pellets. J Microencapsul. 2007, 24: 57-71.
5. Sakarkar DM, Jaiswal SB, Dorle AK. Process for the production of pharmaceutical pellets. Indian Patent Application No. 960/MUM/2004, 2004.
6. Kruder GA. Extrusion in: Kroschwitz J, editors. Encyclopedia of Polymer Science and Engineering. New York: John Wiley and Sons, Inc. 1985. 1: 571-631.
7. Thoma K, Ziegler I. Investigations on the Influence of the type of extruder for pelletization by extrusionspheronization. II. Sphere Characteristics. Drug Dev Ind Pharm. 1998, 24: 413-422.
8. Brietenbach J. Melt Extrusion: From Process to Drug delivery technology. Eur J Pharm Biopharm. 2002, 54: 107-117.
9. Nakamichi K, Nakano T, Yasuura H, et al. The role of the kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin screw extruder. Int J Pharm. 2002, 241: 203-211.
10. Sandra G, Aswin D, Pieterjan K, et al. Comparison between hot-melt extrusion and spray-drying for manufacturing solid dispersions of the graft copolymer of ethylene glycol and vinylalcohol. Pharm Res. 2011, 28: 673-682.
11. Six K, Murphy J, Weuts I, et al. Identification of phase separation in solid dispersions of itraconazole and Eudragit® E100 using microthermal analysis. Pharm Res. 2003, 20: 135-138.
12. Tumuluri SVS, Proddduturi S, Crowley MM, et al. The use of Near-Infrared spectroscopy for the quantitation of a drug in Hot-melt extruded films. Drug Dev Ind Pharm. 2004, 30: 505-511.
13. Crowley MM, Zhang F, Repka MA, et al. Pharmaceutical Applications of Hot Melt Extrusion: Part I. Drug Dev Ind Pharm. 2007, 33: 909-926.
14. Cuff G, Raouf F. A preliminary evaluation of injection molding as a technology to produce tablets. Pharm Tech. 1998, 6: 97-106.
15. Li L, Omar A, Shao ZJ. Characterization of poly(ethylene oxide) as a drug carrier in Hot-melt extrusion. Drug Dev Ind Pharm. 2006, 32: 991-1002.
16. Ahmed HA, Alfredson TV, Birudaraj K, et al. Pharmaceutical composition and process. U.S. Patent 7,795,237, September 14, 2010.
17. Aitken-Nichol C, Zhang F, McGinity JW. Hot melt extrusion of acrylic films. Pharm Res. 1996, 13: 804-808.
18. Follonier N, Doelker E, Cole ET. Evaluation of hot-melt extrusion as a new technique for the production of polymerbased pellets for sustained release capsules containing high loading of freely soluble drugs. Drug Dev Ind Pharm. 1994, 20: 1323-1339.
19. Zhang F, McGinity JW. Properties of sustained release tablets prepared by hot melt extrusion. Pharm Dev Technol. 1999, 4: 241-250.
20. Sandra U, Schilling NH, Shah A, et al. Properties of melt extruded enteric matrix pellets, Eur J Pharm Biopharm. 2010, 74: 352-361.
21. Wu C, McGinity JW. Influence of methylparaben as a solid-state plasticizer on the physicochemical properties of Eudragit RS PO hot-melt extrudates. Eur J Pharm Biopharm. 2003, 56: 95-100.
22. Zhu Y, Shah NH, Malick AW, et al. Solid-state plasticization of an acrylic polymer with chlorpheniramine maleate and triethyl citrate. Int J Pharm. 2002, 241: 301-310.
23. Ghebremeskel NA, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Stability testing of selected solid dispersions. Pharm Res. 2006, 23: 1928-1936.
24. Zhu Y, Shah NH, Malick AW, et al. Influence of a lipophilic thermal lubricant on the processing conditions and drug release properties of chlorpheniramine maleate tablets prepared by hot-melt extrusion. STP Pharm Sci. 2004, 14: 313-318.
25. Follonier N, Doelker E, Cole ET. Various ways of modulating the release of diltiazem hydrochloride from hot-melt extruded sustained release pellets prepared using polymeric materials. J Control Release. 1995, 36: 243-250.
26. Prodduturi S, Urman KL, Otaigbe JU, et al. Stabilization of hot-melt extrusion formulations containing solid solutions using polymer blends. AAPS Pharm Sci Tech. 2007, 8: 50.
27. Repka MA, Battu SK, Upadhye SB, et al. Pharmaceutical applications of hot melt extrusion: part II. Drug Dev Ind Pharm. 2007, 33: 1043-1057.
28. Gamlen M, Eardley C. Continuous extrusion using a raker perkins MP50 multipurpose extruder. Drug Dev Ind Pharm. 1986, 12: 1701-1713.
29. Desai D, Sandhu HK, Zia H, et al. Effect of solid state plasticizers on the physicochemical stability of solid solutions produced by hot-melt extrusion, AAPS Annual Meeting and Exposition. 2006, 10/28/2006-11/2/2006.
30. Shimpi S, Chauhan B, Mahadik KR, et al. Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation. AAPS Pharm Sci Tech. 2004, 5: 43.
31. Zhang F, McGinity JW. Properties of hot-melt extruded theophylline tablets containing poly(vinyl acetate). Drug Dev Ind Pharm. 2000, 26: 931-942.
32. Andrews GP, Jones DS, Diak OA, et al. The manufacture and characterization of hot-melt extruded enteric tablets. Eur J Pharm Biopharm. 2008, 69: 264-273.
33. Mehuys E, Remon J, Vervaet C. Production of enteric capsules by means of hot-melt extrusion. Eur J Pharm Sci. 2005, 24: 207-212.
34. Zheng W, Cerea M, Sauer D, et al. Properties of theophylline tablets powder-coated with methacrylate ester copolymers. STP Pharm Sci. 2004, 14: 319-325.
35. Crowley MM, Zhang F, Koleng JJ, et al. Stability of polyethylene oxide in matrix tablets prepared by hot-melt extrusion. Biomaterials. 2002, 23: 4241-4248.
36. Oshlack B, Chasin M, Huang H, et al. Melt-extruded orally administrable opioid formulations. U.S. Patent 6743442, 2004.
37. Young CR, Dietzsch C, McGinity JW. Compression of controlled-release pellets produced by a hot-melt extrusion and spheronization process. Pharm Dev Technol. 2005, 10: 133-139.
38. Paradkar A, Maheshwari M, Tyagi AK, et al. Preparation and characterization of flurbiprofen beads by melt solidification technique. AAPS Pharm Sci Tech. 2003, 4: 65.
39. Verhoeven E, De Beer TR, Van den MG, et al. Influence of formulation and process parameters on the release characteristics of ethyl cellulose sustained-release minimatrices produced by hot-melt extrusion. Eur J Pharm Biopharm. 2008, 69: 312-319.
40. De Brabander C, Vervaet C, Remon JP. Development and evaluation of sustained release mini-matrices prepared via hot melt extrusion. J Control Release 2003, 89: 235-247.
41. De Brabander C, Vervaet C, Van Bortel L, et al. Bioavailability of ibuprofen from hot-melt extruded minimatrices. Int J Pharm. 2004, 271: 77-84.
42. Fukuda M, Peppas NA, McGinity JW. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. Int J Pharm. 2006, 310: 90-100.
43. Young CR, Dietzsch C, Cerea M, et al. Physicochemical characterization and mechanism of release of theophylline from melt-extruded dosage forms based on a methacrylic acid copolymer. Int J Pharm. 2005, 301: 112-120.
44. Crowley MM, Fredersdorf A, Schroeder B, et al. The influence of guaifenesin and ketoprofen on the properties of hot-melt extruded polyethylene oxide films. Eur J Pharm Sci. 2004, 22: 409-418.
45. Lyons JG, Holehonnur H, Devine DM, et al. The incorporation of an organically modified layered silicate in monolithic polymeric matrices produced using hot melt extrusion. Mater Chem Phys. 2007, 103: 419-426.
46. Lyons JG, Devine DM, Kennedy JE, et al. The use of agar as a novel filler for monolithic matrices produced using hot melt extrusion. Eur J Pharm Biopharm. 2006, 64: 75-81.
47. Bruce LD, Shah NH, Malick WA, et al. Properties of hotmelt extruded tablet formulations for the colonic delivery of 5-amino-salicylic acid. Eur J Pharm Biopharm. 2005, 59: 85-97.
48. Fukuda M, Peppas NA, McGinity JW. Floating hot-melt extruded tablets for gastro-retentive controlled drug release system. J Control Release. 2006, 115: 121-129.
49. Jain SP, Shah S, Rajadhyaksha N, et al. Twice a day ocular inserts of acyclovir by melt extrusion technique. Indian J Pharm Sci. 2007, 69: 562-567.
50. Hagen TA, Lo JB, Thombre AG, et al. Azithromycin dosage forms with reduced side effects. U.S. Patent 6984403, 2006.
51. Vasanthavada M, Wang Y, Haefele T, et al. Application of melt granulation technology using twin-screw extruder in development of high-dose modified-release tablet formulation. J Pharm Sci. 2011, 100(5),1923-1934.
52. Benjamin O, Mark C, Hua-Pin H. Melt-extrusion multiparticulates. U.S. Patent 7,510,727, March 31, 2009.
53. Arya A, Chandra A, Sharma V, et al. Fast dissolving oral films: an innovative drug delivery system and dosage form. Int J Chem Tech Res. 2010, 2: 576-583.
54. Bhyan B, Jangra S, Kaur M, et al. Orally fast dissolving films: Innovations in formulation and technology. Int J Pharm Sci Rev Res. 2011, 9: 9.
55. Repka MA, Mididoddi PK, Stodghill SP. Influence of human nail etching for the assessment of topical onychomycosis therapies. Int J Pharm. 2004, 282: 95-106.
56. Repka MA, Prodduturi S, Stodghill SP. Production and characterization of hot-melt extruded films containing clotrimazole. Drug Develop Ind Pharm. 2003, 29: 757-765.
57. Prodduturi S, Manek RV, Kolling B, et al. Water vapor sorption isotherms of hot-melt extruded hydroxypropyl cellulose films: Effect on physico-mechanical properties, release characteristics and stability. J Pharm Sci. 2004, 93: 3047-3056.
58. McGinity JW, Robinson JR. Effervescence polymeric film drug delivery system. United states patent application, US 20010006677, 2001.
59. Mididoddi PK, Prodduturi S, Repka MA. Influence of Tartaric acid on the bioadhesion and mechanical properties of hot-melt extruded hydroxypropyl cellulose films for the human nail. Drug Dev Ind Pharm. 2006, 32: 1059-1066.
60. Repka MA, McGinity JW. Bioadhesive properties of hydroxypropylcellulose topical films produced by hot-melt extrusion. J Control Release. 2001, 70: 341-351.
61. Mididoddi PK, Repka MA. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm. 2007, 66: 95-105.
62. Prodduturi S, Manek RV, Kolling WM, et al. Solidstate stability and characterization of hot-melt extruded poly(ethylene oxide) films. J Pharm Sci. 2005, 94: 2232-2245.
63. Repka MA, Gutta K, Prodduturi S, et al. Characterization of cellulosic hot-melt extruded films containing lidocaine. Eur J Pharm Biopharm. 2005, 59: 189-196.
64. Repka MA, Munjal M, Elsohly MA, et al. Temper-ature stability and bioadhesive properties of d9-tetrahydrocannabinol incorporated hydroxypropyl cellulose polymer matrix systems. Drug Dev Ind Pharm. 2006, 32: 21-32.
65. Breitenbach A, Wolff H-M. Hot melt TTS for administering rotigotine. U.S Patent application 20050260254, 2005.
66. Cilurzo F, Cupone IE, Minghetti P, et al. Fast dissolving films made of maltodextrins. Eur J Pharm Biopharm. 2008, 70: 895-900.
67. Arunachalam A, Karthikeyan M, Konam K, et al. Solid dispersions: a review. Current Pharm Res. 2010, 1: 82-90.
68. Karanth H, Shenoy VS, Murthy RR. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report. AAPS Pharm Sci Tech. 2006, 7: 87.
69. Sharma DK, Joshi SB. Solubility enhancement strategies for poorly water soluble drugs in solid dispersions-a review. Asian J Pharm. 2007, 1: 9-19.
70. Andrews GP, Jones DS, Tipping S, et al. Influence of drug/polymer ratio on the dissolution enhancement for a poorly water-soluble model drug (BCS Class II) using hot melt extrusion, AAPS Annual Meeting and Exposition. 2009, 11/7/2009-11/12/2009.
71. Fukuda M, Miller D, Peppas NA, et al. Influence of sulfobutyl ether β-cyclodextrin (Captisol®) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion. Int J Pharm. 2008, 350: 88-96.
72. Breitenbach J, Magerlein M. Melt-extruded molecular dispersions. In: Pharmaceutical Extrusion Technology, editors. Ghebre-Sellassie I, Martin C. New York: Marcel Dekker Inc. 2003, 245-260.
73. Rosenberg J, Reinhold U, Liepold B, et al. Solid pharmaceutical dosage formulation. U.S. Patent 20050143404, 2005.
74. Rosenberg J, Reinhold U, Liepold B, et al. Solid pharmaceutical dosage form. U.S. Patent 20070249643, 2007.
75. Tho I, Liepold B, Rosenberg J, et al. Formulation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media. Eur J Pharm Sci. 2010, 40: 25-32.
76. Infeld MH, Phuapradit W, Shah NH, et al. High dose solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate and process for making same. U.S. Patent 7014866, 2006.
77. Zheng X, Yang R, Tang X, et al. Part I: Characterization of solid dispersions of nimodipine prepared by Hot-Melt extrusion. Drug Dev Ind Pharm. 2007, 33: 791-802.
78. Zheng X, Yang R, Zhang Y, et al. Part II: Bioavailability in beagle dogs of Nimodipine solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm. 2007, 33: 783-789.
79. Rambali B, Verreck G, Baert L, et al. Itraconazole formulation studies of the melt extrusion process with mixture design. Drug Dev Ind Pharm. 2003, 29: 641-652.
80. Miller DA MJT, Yang W, Williams RO, et al. Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci. 2006, 96: 361-376.
81. He HB, Yang R, Tang X, et al. In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hotmelt extrusion. Drug Dev Ind Pharm. 2010, 36: 681-687.
82. Ranzani LS, Font J, Galimany F, et al. Enhanced in vivo absorption of CB-1 antagonist in rats via solid solutions prepared by hot-melt extrusion. Drug Dev Ind Pharm. 2011, 37: 694-701.
83. Gryczke A, Schminke S, Maniruzzaman M, et al. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. Colloids Surf B Biointerfaces. 2011, 86: 275-284.
84. Zhu Y, Shah NH, Malick AW, et al. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Drug Dev Ind Pharm. 2006, 32: 569-583.
85. Forster A, Hempenstall J, Tucker I, et al. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm. 2001, 226: 147-161.
86. Munjal M, Stodghill SP, Elsohly MA, et al. Polymeric systems for amorphous d9-tetrahydrocannabinol produced by a hot-melt method. Part I: chemical and thermal stability during processing. J Pharm Sci. 2006, 95: 1841-1853.